Literature DB >> 28284337

Autoimmune limbic encephalitis with anti-contactin-associated protein-like 2 antibody secondary to pembrolizumab therapy.

Michael P Brown1, Pravin Hissaria2, Amy Hc Hsieh3, Christopher Kneebone4, Wilson Vallat5.   

Abstract

Immune checkpoint inhibitors such as Pembrolizumab are used to restore antitumour immune response. It is important to be vigilant of immune mediated adverse events related to such therapy. We report a case of autoimmune limbic encephalitis with Contactin-Associated Protein-like 2 (CASPR2) antibody secondary to Pembrolizumab therapy for metastatic melanoma.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28284337     DOI： 10.1016/j.jneuroim.2016.12.016

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN： 0165-5728            Impact factor:   3.478


  22 in total

Review 1.  Proposed diagnostic and treatment paradigm for high-grade neurological complications of immune checkpoint inhibitors.

Authors:  Dustin Anderson; Grayson Beecher; Nabeela Nathoo; Michael Smylie; Jennifer A McCombe; John Walker; Rajive Jassal
Journal:  Neurooncol Pract       Date:  2018-10-04

Review 2.  Neuroimmune Axes of the Blood-Brain Barriers and Blood-Brain Interfaces: Bases for Physiological Regulation, Disease States, and Pharmacological Interventions.

Authors:  Michelle A Erickson; William A Banks
Journal:  Pharmacol Rev       Date:  2018-04       Impact factor: 25.468

Review 3.  Neurological Complications of Therapeutic Monoclonal Antibodies: Trends from Oncology to Rheumatology.

Authors:  Chandler Gill; Stasia Rouse; Ryan D Jacobson
Journal:  Curr Neurol Neurosci Rep       Date:  2017-08-17       Impact factor: 5.081

Review 4.  Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibition.

Authors:  Peter Chei-Way Pan; Aya Haggiagi
Journal:  Curr Oncol Rep       Date:  2019-11-27       Impact factor: 5.075

Review 5.  Neurologic complications of immune checkpoint inhibitors.

Authors:  Alexandra M Haugh; John C Probasco; Douglas B Johnson
Journal:  Expert Opin Drug Saf       Date:  2020-03-11       Impact factor: 4.250

6.  Immune Checkpoint Inhibitor Associated Autoimmune Encephalitis, Rare and Novel Topic of Neuroimmunology: A Case Report and Review of the Literature.

Authors:  Yining Gao; Jie Pan; Dingding Shen; Lisheng Peng; Zhifeng Mao; Chunxia Wang; Huanyu Meng; Qinming Zhou; Sheng Chen
Journal:  Brain Sci       Date:  2022-06-13

7.  Neurologic complications of immune checkpoint inhibitors.

Authors:  Avi Fellner; Chen Makranz; Michal Lotem; Felix Bokstein; Alisa Taliansky; Shai Rosenberg; Deborah T Blumenthal; Jacob Mandel; Suzana Fichman; Elena Kogan; Israel Steiner; Tali Siegal; Alexander Lossos; Shlomit Yust-Katz
Journal:  J Neurooncol       Date:  2018-01-13       Impact factor: 4.130

Review 8.  Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives.

Authors:  Lidia M Yshii; Reinhard Hohlfeld; Roland S Liblau
Journal:  Nat Rev Neurol       Date:  2017-11-06       Impact factor: 42.937

Review 9.  LGI1, CASPR2 and related antibodies: a molecular evolution of the phenotypes.

Authors:  Sophie N M Binks; Christopher J Klein; Patrick Waters; Sean J Pittock; Sarosh R Irani
Journal:  J Neurol Neurosurg Psychiatry       Date:  2017-10-21       Impact factor: 10.154

10.  Neurologic autoimmunity and immune checkpoint inhibitors: Autoantibody profiles and outcomes.

Authors:  Elia Sechi; Svetomir N Markovic; Andrew McKeon; Divyanshu Dubey; Teerin Liewluck; Vanda A Lennon; A Sebastian Lopez-Chiriboga; Christopher J Klein; Michelle Mauermann; Sean J Pittock; Eoin P Flanagan; Anastasia Zekeridou
Journal:  Neurology       Date:  2020-08-13       Impact factor: 9.910
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.